Pulmonx Corporation (LUNG) Reports 75.8% Collateral Ventilation Conversion
Pulmonx (LUNG) reported 75.8% of patients converted from CV+ to CV− after AeriSeal treatment in the CONVERT Trial. 88.9% of evaluable patients achieved significant target-lobe volume reduction with Zephyr Valves. AeriSeal is under pivotal evaluation, with CONVERT II results needed for U.S. PMA application.
How this was made

The 30-second read
Why it matters
The reported conversion and target-lobe reduction rates strengthen the efficacy narrative for the treatment pathway and set expectations for upcoming six-month results tied to a potential U.S. PMA application for AeriSeal.
Market read
Traders can update probabilities for Zephyr pathway efficacy now and for AeriSeal’s PMA timeline as CONVERT II six-month results approach.
What to watch
Durability and safety details are not provided here; traders may wait for full endpoints, adverse event profile, and regulatory submission timing clarity before repricing risk.
Background
Pulmonx is evaluating AeriSeal (collateral ventilation conversion) and Zephyr valves in the CONVERT program, with CONVERT II planned to generate additional pivotal data.
Ticker impact
Pulmonx reports CONVERT trial results, with 75.8% converting after AeriSeal and 88.9% achieving target-lobe reduction with Zephyr valves at 45 days.
Likely upward bias as traders price improved clinical efficacy and potential future PMA progress for AeriSeal.
The article provides specific, trial-level efficacy percentages and a stated regulatory pathway (six-month results supporting a U.S. PMA), which can drive biotech sentiment and expectations, though it is not an approval or filing yet.
Market effects
Reinforces investor appetite for endobronchial valve and collateral ventilation conversion approaches in COPD/air-trapping, potentially lifting sentiment across similar interventional pulmonology names.
Limited direct regional impact; primarily affects US-listed small-cap biotech sentiment.
Moderate, as trial efficacy data can influence global expectations for device-based COPD interventions, but no cross-border regulatory decision is reported.
Counterpoint
AeriSeal remains under pivotal evaluation, so the market may discount the conversion headline until CONVERT II six-month results are available.
Key entities
- companyPulmonx Corporation
Reports CONVERT trial efficacy: 75.8% conversion after AeriSeal and 88.9% target-lobe reduction with Zephyr valves at 45 days, persisting through 12 months.
- productAeriSeal
Collateral ventilation conversion treatment evaluated in CONVERT; pivotal evaluation continues with CONVERT II six-month results needed for PMA support.
- productZephyr valves
Endobronchial valves evaluated after AeriSeal in CONVERT; 88.9% achieved clinically significant target-lobe volume reduction at 45 days.
- clinical_programCONVERT Trial
Clinical evidence source for the reported conversion and valve efficacy outcomes.
